Since DRP1 inhibition could potentially restore the functional aspects of TP53, DRP1 inhibition in combination with venetoclax treatment could potentially improve the therapeutic efficacy of venetoclax in TP53mut AML. Here, TP53 is linked to acute myeloid leukemia.